ClinicalTrials.gov
public full text
Public Domain
Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?
Modulation of the renin angiotensin system by the chronic hepatitis C virus treatment either by (Daclatasvir and Sofosbuvir), (Daclatasvir and Sofosbuvir plus Ribavirin), or (Ribavirin and Interferon) protocols could give an explanation for the low incidence of COVID-19 among Egyptian population. Adding it may play a role in COVID 19 prophylaxis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- COVID-19: Herd Immunity Study in the Czech Republic#915151
- Post-COVID-19-Zustand - klinische Phänotypisierung in der Praxis / Karen Humkamp ; Kathrin Reetz, Lisa Wagels#1097142
- Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19#895861
- Book chapters: Covid-19. A origem do vírus feito para infectar humanos#717903
- COVID-19 sürecinin beden eğitimi ve spor dersine yansımalarının incelenmesi#1167717
Record · ID 918629
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive